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Summary
Background Ovarian tissue cryopreservation with later reimplantation has been shown to preserve fertility in adult 
women, but this approach remains unproven and experimental in children and adolescents. We aimed to assess the 
use of the Edinburgh selection criteria for ovarian tissue cryopreservation in girls and young women with cancer to 
determine whether we are oﬀ ering this invasive procedure to the patients who are most at risk of premature ovarian 
insuﬃ  ciency.
Methods Cryopreservation of ovarian tissue has been selectively oﬀ ered to girls and young women with cancer who 
met the Edinburgh selection criteria since 1996. Between Jan 1, 1996, and June 30, 2012, 410 female patients younger 
than 18 years at diagnosis were treated for cancer (including leukaemia and brain tumours) at the Edinburgh 
Children’s Cancer Centre, which serves the whole South East of Scotland region. We determined the ovarian status of 
these patients from review of clinical records and classiﬁ ed them as having premature ovarian insuﬃ  ciency or not, or 
as unable to be determined. Patients younger than 12 years at time of data cutoﬀ  (Jan 31, 2013) were excluded from the 
analysis.
Findings 34 (8%) of the 410 patients met the Edinburgh selection criteria and were oﬀ ered ovarian tissue cryo-
preservation before starting cancer treatment. 13 patients declined the procedure and 21 consented, and the procedure 
was completed successfully in 20 patients. Of the 20 patients who had ovarian tissue successfully cryopreserved, 
14 were available for assessment of ovarian function. Of the 13 patients who had declined the procedure, six were 
available for assessment of ovarian function. Median age at the time of follow-up for the 20 assessable patients was 
16·9 years (IQR 15·5–21·8). Of the 14 assessable patients who had successfully undergone ovarian cryopreservation, 
six had developed premature ovarian insuﬃ  ciency at a median age of 13·4 years (IQR 12·5–14·6), one of whom also 
had a natural pregnancy. Of the six assessable patients who had declined the procedure, one had developed premature 
ovarian insuﬃ  ciency. Assessment of ovarian function was possible for 141 of the 376 patients who were not oﬀ ered 
cryopreservation; one of these patients had developed premature ovarian insuﬃ  ciency. The cumulative probability of 
developing premature ovarian insuﬃ  ciency after treatment was completed was signiﬁ cantly higher for patients who 
met the criteria for ovarian tissue cryopreservation than for those who did not (15-year probability 35% [95% CI 10–53] 
vs 1% [0–2]; p<0·0001; hazard ratio 56·8 [95% CI 6·2–521·6] at 10 years).
Interpretation The results of this analysis show that the Edinburgh selection criteria accurately identify the few girls 
and young women who will develop premature ovarian insuﬃ  ciency, and validate their use for selection of patients 
for ovarian tissue cryopreservation. Further follow-up of this cohort of patients is likely to allow reﬁ nement of the 
criteria for this experimental procedure in girls and young women with cancer.
Funding UK Medical Research Council.
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Introduction
Childhood cancer survival has improved greatly over the 
past ﬁ ve decades. About 80% of children with cancer 
will be alive 5 years after diagnosis and about 70% will 
be alive and cured of their original cancer 10 years after 
diagnosis.1 However, some cancer treatments can 
compromise ovarian function in children.2–4 The 
increasing life expectancy of children with cancer has 
led to a growing population of girls and young women 
who are at risk of developing premature ovarian 
insuﬃ  ciency. Most girls and young women treated for 
cancer will retain a window of opportunity for fertility; 
however, for those at high risk of premature ovarian 
insuﬃ  ciency the options for fertility preservation are 
few and experimental.
Ovarian tissue cryopreservation is an important 
development for fertility preservation in girls and young 
women at risk of premature ovarian insuﬃ  ciency as a 
result of treatment for cancer.5–8 At least 30 pregnancies 
after orthotopic reimplantation of frozen–thawed ovarian 
cortex have been reported worldwide,5 showing that this 
approach is viable in adults, although the success rate is 
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unclear because the total number of women in whom 
frozen–thawed ovarian tissue has been reimplanted is 
unknown. The procedure remains unproven and 
experimental in girls and young women.
Evidence from case series and reviews9,10 has suggested 
that the collection of ovarian tissue for freezing by 
laparoscopy under a general anaesthetic is safe and 
feasible in prepubertal girls as well as in adult women. 
The procedure is invasive, and can carry an unacceptable 
operative risk in some children with cancer who might 
be immunocompromised and pancytopenic and are 
therefore at increased risk of bleeding and infection. 
Haematological cancer in particular can involve the 
ovary,11,12 precluding later replacement of tissue to restore 
fertility. These uncertainties, and the unknown 
eﬀ ectiveness of the procedure for the restoration of 
fertility, dictate that it should only be oﬀ ered to girls and 
young women who are at high risk of premature ovarian 
insuﬃ  ciency and who will have a substantially reduced 
opportunity for fertility. Accurate identiﬁ cation of these 
patients requires that the risk of premature ovarian 
insuﬃ  ciency, which is determined by the nature of the 
treatment to be delivered and not the disease itself, can 
be assessed at the time of diagnosis.4 However, in 
children, the full consequences of treatment with respect 
to reproductive function are not fully known and will 
take several decades to be fully realised.13,14 Thus an 
accurate fertility prognosis cannot always be obtained 
before the start of treatment. On the basis of these 
considerations, we have previously proposed that factors 
that aﬀ ect the assessment of an individual patient for 
invasive fertility preservation techniques can be usefully 
grouped as intrinsic (ie, related to the patient herself and 
her present state of health) and extrinsic (ie, related 
largely to the anticipated treatment and the availability of 
appropriate expertise for the techniques proposed).15
With the now proven success of ovarian tissue 
cryopreservation in adult women,5 it is important to 
establish if this experimental technique is being oﬀ ered to 
the correct young patients—ie, those who are at high risk 
for the development of premature ovarian insuﬃ  ciency, 
can safely undergo laparoscopic surgery, and have a good 
long-term prognosis. The Edinburgh selection criteria for 
ovarian tissue cryopreservation have been previously 
reported,4,9 having been developed after multidisciplinary 
discussion in 1996 and slightly revised in 2000. The aim of 
this study is to assess the accuracy of patient selection for 
ovarian tissue cryopreservation in a single centre that has 
oﬀ ered this experimental procedure (as part of this 
approved study) to selected children and teenagers with 
cancer since 1996, by comparing the prevalence of 
premature ovarian insuﬃ  ciency in those who were and 
were not oﬀ ered the procedure.
Methods
Study design and participants
The study cohort consisted of all female patients treated 
for cancer (including leukaemia and brain tumours) at the 
Edinburgh Children’s Cancer Centre who were younger 
than 18 years at diagnosis between Jan 1, 1996, and 
June 30, 2012. We aimed to assess the relation between 
whether or not patients had been oﬀ ered ovarian tissue 
cryo preservation and whether they had premature ovarian 
insuﬃ  ciency at the time of their most recent assessment. 
A risk assessment for fertility preservation was made for 
all patients before the start of treatment,15 and cryo-
preservation of ovarian tissue was oﬀ ered to those patients 
who met the Edinburgh selection criteria (panel 1). These 
criteria were developed after discussion within the 
multidisciplinary team and were approved by a research 
ethics committee. We used knowledge of the relevant 
scientiﬁ c literature and our own experience to make an 
initial assessment at diagnosis of whether an individual 
patient with a new diagnosis of cancer had a greater than 
50% risk of premature ovarian insuﬃ  ciency. The 
development of a treatment plan for each patient allowed 
a decision about the risk of premature ovarian 
insuﬃ  ciency. Most of the patients identiﬁ ed as being at 
high risk of premature ovarian insuﬃ  ciency were planned 
to be treated with high-dose alkylating agent-based 
regimens or radiotherapy to a ﬁ eld that would include the 
ovaries. We obtained written informed consent from 
parents and, where possible, patients for ovarian tissue 
cryopreservation.
This study was done with the approval of the Lothian 
Research Ethics Committee.
Procedures
In those patients who consented to the procedure, ovarian 
tissue was obtained laparoscopically under general 
anaesthetic and cryopreserved. Generally, three to ﬁ ve 
ovarian cortical strips from one ovary were dissected with 
scissors, without diathermy, with the aim of removing 
roughly 70% of the ovarian cortex. Thin strips (not more 
than 1·5 mm thick) were collected into Liebovitz medium 
and cryopreserved as previously described.16 A whole 
ovary could be obtained from very young patients for 
whom the cortex could not be dissected. A further small 
biopsy sample was taken in all cases for pathological 
examination to investigate the possibility of malignant 
Panel 1: The Edinburgh selection criteria 
• Age younger than 35 years
• No previous chemotherapy or radiotherapy if aged 
15 years or older at diagnosis, but mild, non-gonadotoxic 
chemotherapy acceptable if younger than 15 years
• A realistic chance of surviving for 5 years
• A high risk of premature ovarian insuﬃ  ciency (>50%)
• Informed consent (from parents and, where possible, 
patient)
• Negative serology results for HIV, syphilis, and hepatitis B
• Not pregnant and no existing children
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contamination. Biopsy samples are stored in the vapour 
phase of liquid nitrogen at the Scottish National Blood 
Transfusion Service Tissue Establishment (Edinburgh, 
UK) under licence from the UK Human Tissue Authority 
and, for part of the time period reported, the Human 
Fertilisation and Embryology Authority.
Ovarian status was recorded for the whole surviving 
cohort who were aged 12 years or older on Jan 31, 2013, 
from review of their medical notes from diagnosis and 
when they attended routine follow-up assessments. A 
typical patient is seen 24 times in the 5 years after 
completion of treatment; thereafter all patients are seen 
at least annually. Premature ovarian insuﬃ  ciency was 
deﬁ ned as the documented presence of at least two of 
three identifying features: amenorrhoea for at least 
4 months; serum follicle stimulating hormone greater 
than 25 IU/L on at least two occasions; and low 
(<150 pmol/L) serum oestradiol concomitant with raised 
(>25 IU/L) follicle stimulating hormone. The absence of 
premature ovarian insuﬃ  ciency was conﬁ rmed by one or 
more of three identifying features: premenarcheal, but 
progressing normally through puberty; having regular 
menses while not taking hormonal contraception; or 
normal concentrations of gonadotropins and oestradiol. 
Ovarian status could not be determined in children 
younger than 12 years, because the measurement of 
gonadotropins and oestradiol in girls younger than 
12 years is not a reliable measure of ovarian function, or 
in individuals taking hormonal contraception.
Statistical analysis
We used the Kaplan-Meier method17 with premature 
ovarian insuﬃ  ciency as the deﬁ ned event. Since patient 
classiﬁ cation into the premature ovarian insuﬃ  ciency 
group occurred after the actual date of onset of 
premature ovarian insuﬃ  ciency, we discretised the 
15 years after diagnosis into calendar years, and recorded 
each assessment of premature ovarian insuﬃ  ciency 
occurring in the year after diagnosis as a premature 
ovarian insuﬃ  ciency event in that year. We then 
calculated life tables for the patients who were oﬀ ered 
ovarian tissue cryopreservation (the oﬀ ered group) and 
those who were not oﬀ ered the procedure (the not-
oﬀ ered group) as cumulative event-free probabilities for 
each year of follow-up after diagnosis.
We derived p values to test the null hypothesis that the 
frequency of premature ovarian insuﬃ  ciency occurrences 
were distributed evenly between the two groups. We also 
calculated hazard ratios (HRs) to quantify any diﬀ erences 
in the proportion of patients with premature ovarian 
insuﬃ  ciency between the two groups. The HR for each 
year was calculated as the ratio of observed-to-expected 
occurrences of premature ovarian insuﬃ  ciency in the 
oﬀ ered group in that year, divided by the ratio of 
observed-to-expected occurrences of premature ovarian 
insuﬃ  ciency in the not-oﬀ ered group in that year, with 
the observed and expected values taken from the 
intermediate calculations used to derive the Kaplan-
Meier cumulative probabilities.
We calculated HRs using Microsoft Excel for Mac 
(version 14.3.7) and did the Kaplan-Meier analyses, 
including calculation of CIs and p values, using the 
KMsurv version 0.1-5 package for R version 2.15.3.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. All authors had access to the raw data (apart 
from TWK, who had access to anonymised raw data). 
The corresponding author had full access to all the data 
in the study and had ﬁ nal responsibility for the decision 
to submit for publication.
Results
The eligible study population consisted of 410 patients 
(ﬁ gure 1). Ovarian status could not be determined in 
children younger than 12 years (n=98), and 18 individuals 
taking hormonal contraception (combined oral 
contraceptive pill in all cases) were excluded from 
analyses. At the time of data censoring (Jan 31, 2013), an 
additional four patients who had not been oﬀ ered ovarian 
tissue cryopreservation were still receiving cancer 
treatment, and we were unable to classify ovarian function 
in a further 42 patients in the same group because of 
incomplete information in their medical records. Median 
follow-up for the assessable patients who were oﬀ ered 
and underwent ovarian tissue cryopreservation (n=14) 
was 6·0 years (IQR 3·5–14·9); for those who were oﬀ ered 
the procedure but declined (n=6) it was 10·9 years 
(7·4–13·7) and for those who were not oﬀ ered the 
procedure (n=141) it was 10·7 years (6·1–13·8).
Ovarian tissue cryopreservation was oﬀ ered to 
34 patients, of whom 21 underwent the procedure and 
13 declined. 376 patients were not oﬀ ered the procedure. 
The median age of the cohort of patients who were 
oﬀ ered cryopreservation and were assessable (n=20, 
ﬁ gure 1) was 16·9 years (IQR 15·5–21·8) at data cutoﬀ  for 
this analysis; the median age of assessable patients in the 
not-oﬀ ered group (n=141) was 17·9 years (15·6–22·0). 
The procedure was unsuccessful in one individual (the 
second case undertaken) because of technical problems 
with surgical equipment, with no adverse eﬀ ect on the 
patient. Of the patients who underwent ovarian 
cryopreservation, a whole ovary was obtained in the two 
youngest patients (table); the other patients had ovarian 
cortical strips taken from one ovary.
Of the 20 patients in the oﬀ ered group who had ovarian 
tissue successfully cryopreserved, four were younger 
than 12 years at the time of last follow-up, one had died, 
and one was using hormonal contraception; 14 patients 
were aged 12 years or older and available for assessment 
of ovarian function. Of these 14, six had developed 
premature ovarian insuﬃ  ciency at a median age of 
13·4 years (IQR 12·5–14·6), after a median interval since 
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diagnosis of 1·7 years (0·8–2·4), and eight had normal 
ovarian function at a median age of 21·9 years 
(16·2–27·7). One patient who developed premature 
ovarian insuﬃ  ciency subsequently had a successful 
natural pregnancy, as reported previously.18
Of the 13 patients who were oﬀ ered cryopreservation 
but declined the procedure (ﬁ gure 1), three were deceased 
and three were younger than 12 years at the time of last 
follow-up; one was lost to follow-up. Therefore, six were 
available for assessment, of whom one had developed 
premature ovarian insuﬃ  ciency at age 13·4 years 
(interval 7·9 years). Median age of the ﬁ ve patients 
without premature ovarian insuﬃ  ciency was 16·7 years 
(IQR 15·4–17·9). Thus premature ovarian insuﬃ  ciency 
was identiﬁ ed in a total of seven (35%) of 20 assessable 
patients in the group oﬀ ered ovarian cryopreservation.
Of the 376 patients not oﬀ ered ovarian 
cryopreservation, 81 were deceased at the time of 
assessment, 91 were younger than 12 years, 17 were 
using hormonal con traception, four were still receiving 
cancer treatment, and information about ovarian status 
was incomplete for 42 (ﬁ gure 1). Of the 141 who were 
not oﬀ ered cryopreservation and for whom ovarian 
function is known, 140 did not have premature ovarian 
insuﬃ  ciency at a median age 17·9 years (IQR 15·6–22·0). 
Of these, 112 had achieved menarche, 17 were 
premenarchal but aged 12 years or older and were 
progressing normally through puberty, and 11 had 
hypogonadotropic hypogonadism as a result of cranial 
irradiation treatment for brain tumours. Premature 
ovarian insuﬃ  ciency was conﬁ rmed in only one patient 
in this group, who developed premature ovarian 
insuﬃ  ciency at age 15·0 years (2·9 years after diagnosis) 
after a successful allogeneic bone marrow trans-
plantation for relapsed acute myeloid leukaemia with 
busulfan and cyclophosphamide conditioning. She was 
not oﬀ ered cryopreservation of ovarian tissue at the 
time of original diagnosis because she did not meet the 
criteria (low risk of premature ovarian insuﬃ  ciency), 
nor at relapse because of the urgency of the need for 
further treatment, when she was believed to be too 
unwell to undergo a laparoscopic procedure.
Therefore, by 9 years from diagnosis (the interval to 
the last premature ovarian insuﬃ  ciency event), 
seven (35%) of 20 patients oﬀ ered ovarian tissue 
cryopreservation had developed premature ovarian 
insuﬃ  ciency, compared with one (1%) of 141 of those 
not oﬀ ered ovarian tissue cryopreservation. The 
cumulative probability of developing premature ovarian 
insuﬃ  ciency after treatment was completed was 
signiﬁ cantly higher for the patients oﬀ ered ovarian 
tissue cryopreservation than for those who were not 
oﬀ ered ovarian tissue cryopreservation (15-year 
probability 35% [95% CI 10–53] vs 1% [0–2]; p<0·0001; 
HR 56·8 [95% CI 6·2–521·6] at 10 years; ﬁ gure 2).
In addition to the assessed risk of premature ovarian 
insuﬃ  ciency as a result of the planned treatment, 
another of the Edinburgh selection criteria is that the 
patient has to have a realistic chance of surviving for 
5 years (panel 1). In our cohort, four (12%) of 34 patients 
410 female cancer patients aged younger than 18 years at diagnosis
34 were oﬀered
 cryopreservation
20 had tissue
 cryopreserved
13 declined procedure 1 procedure unsuccessful (patient later
   died, unrelated to procedure) 
376 were not oﬀered
 cryopreservation
81 died
91 younger than 12 years 
17 on COCP
 4 were still on cancer treatment 
42 had insuﬃcient follow-up information
1 died
4 younger than 
    12 years 
1 on COCP
1 declined because of
 poor communication
1 declined because of
 a uterine factor*
2 declined because
 of parental choice
9 declined because
 patient was too unwell
1 younger than
 12 years 
3 died
2 younger than 
   12 years 
1 lost to follow-up
14 available for assessment of ovarian function 6 available for assessment of ovarian function 141 available for assessment of ovarian function
Figure 1: Study proﬁ le
COCP=combined oral contraceptive pill. *Treatment plan meant that there was a high chance that the patient would receive radiation to her pelvis and uterus at a very young age.
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in the oﬀ ered group (or one [5%] of 20 who had their 
ovarian tissue cryopreserved) were deceased at the time 
of analysis, compared with 81 (22%) of 376 in the not-
oﬀ ered group; thus, overall this criterion was met.
13 patients declined the oﬀ er of ovarian tissue 
cryopreservation. The most common reason for this 
decision (in nine cases) was that both the medical team 
and the patient’s parents believed that she was too unwell 
to undergo an additional laparoscopic procedure. In two 
patients, the parents declined to proceed with ovarian 
tissue cryopreservation for no speciﬁ c reason when it was 
believed to be medically appropriate. For another patient, 
severe language diﬃ  culties contributed to the investigators 
being unable to obtain informed consent for the procedure. 
For the remaining patient, who had a vaginal rhabdomyo-
sarcoma, the parents decided against the procedure 
because there was a high chance that their daughter would 
receive radiation to her pelvis and uterus at a very young 
age, making it highly unlikely that she would be able to 
carry a pregnancy successfully in the future.
Discussion
The results of our analysis show that the Edinburgh 
selection criteria accurately predict which girls and young 
women will or will not develop premature ovarian 
insuﬃ  ciency. These ﬁ ndings validate the use of these 
criteria for patient selection for ovarian tissue 
cryopreservation before the start of cancer treatment.
High survival following childhood cancer has led to an 
increased focus on the late eﬀ ects of treatment,19,20 and the 
eﬀ ect of cancer treatment on fertility is a prime concern to 
Diagnosis Age at cryo-
preservation 
(years)
Method of ovarian 
tissue collection
Complications 
from procedure
Duration since 
cryopreservation 
(years)
Age at last 
assessment 
(years)
Ovarian
function
1 Hodgkin’s lymphoma* 14·9 Laparoscopic cortical strip None 15·8 30·2 Not POI
2 Ewing’s sarcoma 9·2 Procedure failed None ·· ·· Deceased
3 Ewing’s sarcoma (pubic bone) 14·9 Laparoscopic cortical strip None 16·6 25·6 POI (plus one child)
4 Sacral ependymoma 11·3 Laparoscopic cortical strip None 15·8 24·5 Not POI
5 Hodgkin’s lymphoma 13·7 Laparoscopic cortical strip None 15·6 28·9 Not POI
6 Hodgkin’s lymphoma 11·0 Laparoscopic cortical strip None 14·7 ·· On COCP
7 Chronic granulocytic leukaemia 9·9 Laparoscopic cortical strip None 12·2 21·7 Not POI
8 Rhabdomyosarcoma 5·3 Laparoscopic cortical strip None 8·2 13·1 POI
9 Ewing’s sarcoma (pelvic) 9·8 Laparoscopic cortical strip None 6·7 15·6 POI
10 Uterine cervix rhabdomyosarcoma† 16·4 Laparoscopic cortical strip None 5·1 17·5 Not POI
11 Hodgkin’s lymphoma‡ 14·0 Laparoscopic cortical strip None 3·2 17·2 POI
12 Abdominal embryonal rhabdomyosarcoma 7·9 Laparoscopic cortical strip None ·· ·· Deceased
13 Ewing’s sarcoma 12·1 Laparoscopic cortical strip§ None 3·9 15·2 POI
14 Hodgkin’s lymphoma 12·7 Laparoscopic cortical strip None 3·3 14·3 POI
15 Metastatic medulloblastoma 8·1 Laparoscopic cortical strip None 2·9 ·· Not assessed
16 Hodgkin’s lymphoma 15·2 Laparoscopic cortical strip None 1·9 16·9 Not POI
17 Alveolar rhabdomyosarcoma 10·5 Laparoscopic cortical strip None 1·4 ·· Not assessed
18 Embryonal rhabdomyosarcoma 3·0 Oophorectomy None 1·4 ·· Not assessed
19 Ewing’s sarcoma 12·0 Laparoscopic cortical strip None 1·4 13·5 Not POI
20 Undiﬀ erentiated sarcoma 12·3 Laparoscopic cortical strip§ None 1·0 13·4 Not POI
21 Wilms’ tumour 1·2 Oophorectomy None 0·6 ·· Not assessed
All tissue was collected before chemotherapy (with or without radiotherapy) were given, apart from patients 1 and 11. Ovarian function was not assessed in patients who were younger than 12 years at the time 
of data censoring. POI=premature ovarian insuﬃ  ciency. COCP=combined oral contraceptive pill. *Tissue collected after relapse of disease 21 months after initial radiotherapy. †Diagnosis changed to Müllerian 
adenosarcoma shortly after tissue cryopreservation. ‡Tissue collected after relapse of disease 7 months after initial radiotherapy. §Metastatic deposits identiﬁ ed on cortical strip.
 Table: Characteristics and ovarian function for patients who underwent laparoscopy for fertility preservation, by patient number
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young women.21 Although several options might be 
available to adult women, including ovarian tissue, oocyte, 
and embryo cryostorage, none are established in girls and 
adolescents, although ovarian tissue cryopreservation has 
been proposed.9,10 Because patient selection is crucial for 
this experimental procedure and the outcome might not 
be known for many years, we have analysed 15 years of 
experience in a regional children’s cancer centre. Applying 
the Edinburgh selection criteria, ovarian tissue cryo-
preservation was oﬀ ered to 8% of our patients since 1996, 
and done in 5%. The procedure was safe and without 
surgical complications. Through the application of our 
criteria, we have oﬀ ered ovarian tissue cryopreservation to 
all but one of our patients who have gone on develop 
premature ovarian insuﬃ  ciency so far. We believe that the 
Edinburgh selection criteria provide a solid scientiﬁ c basis 
for the identiﬁ cation of patients at risk of premature 
ovarian insuﬃ  ciency and to whom this invasive procedure 
may be oﬀ ered (panel 2).
Some girls and young women treated for cancer are at 
risk of premature ovarian insuﬃ  ciency and infertility. 
Overall, data from the Childhood Cancer Survivor 
Study14 suggest that the relative risk of premature 
ovarian insuﬃ  ciency is roughly 13 by age 40 years, 
compared with sibling controls, although 92% of 
survivors did not have premature ovarian insuﬃ  ciency 
by that age.22 However, survivors who have not developed 
premature ovarian insuﬃ  ciency are still at increased 
risk of infertility,14 as are women treated for cancer in 
adulthood.23 Accurate identiﬁ cation of girls and young 
women at high risk of premature ovarian insuﬃ  ciency 
is important so as to allow the application of an 
experimental technique to those patients most likely to 
beneﬁ t in the long term.
We have oﬀ ered ovarian tissue cryopreservation for 
more than 15 years to selected female patients at our 
regional children’s cancer centre. The key selection 
criteria are the expected eﬀ ect of proposed treatment on 
ovarian function, and the likelihood of survival, as well as 
surgical considerations with respect to the safety of the 
procedure. The eﬀ ect of treatment can be classiﬁ ed by 
risk,24 with high-risk treatment involving high doses of 
alkylating agent-based treatment or abdominopelvic 
irradiation. Development of the treatment plan in all 
cases allowed a decision about the risk of premature 
ovarian insuﬃ  ciency, but disease response or relapse will 
often require the treatment plan to be revised. This issue 
is exempliﬁ ed by the single patient in the group not 
oﬀ ered cryopreservation who developed premature 
ovarian insuﬃ  ciency: she did not meet the criteria for 
ovarian tissue cryopreservation at the time of original 
diagnosis, but when she presented with a relapse she was 
believed to be too unwell to justify the surgical 
intervention needed. Similarly, the patient with cervical 
rhabdomyosarcoma shows the importance of the con-
temporaneous nature of the decision. She was oﬀ ered 
ovarian tissue cryopreservation because of her initial 
pathological diagnosis, with the intended treatment 
including use of an alkylating agent and radiation to her 
pelvis. The ovarian tissue cryopreservation procedure 
was done successfully, but shortly after the procedure the 
diagnosis was changed to Müllerian adenosarcoma, and 
she did not need any potentially gonadotoxic treatment. 
This patient was therefore not at high risk of premature 
ovarian insuﬃ  ciency, but she is nevertheless included in 
this analysis because the initial assessment was made on 
the basis of the initial (later revised) diagnosis; the key 
issue is that the assessment has to be based on the 
intended treatment plan.
Although the duration of follow-up in the present 
analysis is up to 16·6 years, for many of the patients the 
duration is much less (as little as a few months), so 
additional young women survivors might develop 
premature ovarian insuﬃ  ciency with time. Continued 
follow-up is therefore necessary to test whether the 
substantial diﬀ erence in prevalence of premature ovarian 
Panel 2: Research in context
Systematic review
For prepubertal girls and young women with cancer who are 
unwilling to delay the start of chemotherapy, cryopreservation 
of ovarian tissue is the only fertility preservation option 
available. So far, 30 livebirths have been reported after 
reimplantation of cryopreserved ovarian tissue in adult 
women:5 none have been reported using ovarian tissue from 
prepubertal girls. Most girls and young women treated for 
cancer will retain a window of opportunity for fertility in the 
future once they have survived their original cancer, 
dependent on the nature of the patients’ planned treatment 
(which might change dependent on their response).4 The 
identiﬁ cation of those patients who are at the highest risk of 
loss of fertility, thus justifying the use of an invasive 
experimental approach, is crucial. No previous study has 
addressed the accuracy and safety with which this procedure 
can be oﬀ ered to girls and adolescents with cancer who are at 
highest risk of developing premature ovarian insuﬃ  ciency. 
Interpretation
We have shown that the Edinburgh selection criteria predict 
which young female patients with cancer are more likely to 
develop premature ovarian insuﬃ  ciency and are therefore 
most likely to beneﬁ t from ovarian tissue cryopreservation. 
The procedure is invasive, requiring surgery, and the success 
rate in terms of future livebirths remains unknown. A 
minority of girls and young women with cancer are at high 
risk of premature ovarian insuﬃ  ciency and, because this 
approach remains experimental,7 it is necessary to limit 
ovarian tissue cryopreservation to those patients at high risk 
of premature ovarian insuﬃ  ciency. Future research should 
focus on the development of this new and experimental 
service for girls and young women with cancer who are at 
highest risk of premature ovarian insuﬃ  ciency, but who have 
a realistic chance of survival.
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insuﬃ  ciency between the group oﬀ ered cryopreservation 
and that not oﬀ ered it at this point persists, or perhaps 
widens further, and to allow assessment of other 
outcomes such as fertility.
Although the diagnosis of premature ovarian 
insuﬃ  ciency used in our analysis is robust, the data are 
limited by the large number of patients for whom ovarian 
function could not be determined (because some patients 
were still at a prepubertal age, some were using hormonal 
contraception, and some did not have information about 
ovarian function in their medical records). The diagnosis 
of premature ovarian insuﬃ  ciency requires measurement 
of follicle stimulating hormone and oestradiol, which are 
unreliable in prepubertal girls. Anti-Müllerian hormone 
is not established as part of the diagnosis of premature 
ovarian insuﬃ  ciency, but might become a useful 
biomarker in children because it is measurable in girls of 
all ages and shows a progressive rise through childhood.25 
The concentration of anti-Müllerian hormone falls during 
cancer treatment in prepubertal and adolescent girls13 as 
it does in adults,26 with clearly divergent patterns of 
recovery after treatment completion in accordance with 
gonadotoxicity risk.13,27 Measurement of anti-Müllerian 
hormone even in prepubertal cancer survivors might 
thus be of diagnostic value for the identiﬁ cation of 
individuals with premature ovarian insuﬃ  ciency in 
whom early sex steroid treatment can be introduced for 
induction of puberty.
The inability to conﬁ rm or refute premature ovarian 
insuﬃ  ciency in some women might have biased our 
analysis. The proportion of prepubertal girls was similar 
in the groups who were and were not oﬀ ered 
cryopreservation. All women taking hormonal con-
traception were taking it to prevent pregnancy rather than 
as hormone replacement, although premature ovarian 
insuﬃ  ciency might have developed after the start of oral 
contraceptive use in some individuals, and therefore gone 
undetected in our analysis. In patients with an incomplete 
record, evidence of premature ovarian insuﬃ  ciency 
would probably have been noted, whereas normal ovarian 
function might not have been recorded. Thus, although 
some individuals within the group not oﬀ ered 
cryopreservation (prepubertal, oral contraceptive users, or 
those with incomplete information about ovarian 
function) might have premature ovarian insuﬃ  ciency 
that we were unable to identify, identiﬁ cation of these 
cases would be very unlikely to give a similar prevalence 
of premature ovarian insuﬃ  ciency to that in the group 
who were oﬀ ered the procedure.
Reimplantation of ovarian tissue has resulted in 
successful pregnancies in some adult women, conﬁ rming 
the potential of this approach.5 No cases have been 
reported of pregnancy after ovarian tissue cryo-
preservation in childhood or adolescence. However, 
ﬁ ndings from a recent study in an ovine model28 have 
shown that grafting immature ovarian tissue can restore 
spontaneous puberty and fertility,28 and a mature oocyte 
at metaphase II has been derived from a prepubertal 
ovarian biopsy sample xenografted into a mouse.29 In our 
study population, none of the young women has yet 
requested use of their stored tissue, nor are we aware of 
such use for fertility elsewhere. The authors of two case 
reports30,31 have described the replacement of ovarian 
tissue in adolescents for the purpose of oestrogen 
production for pubertal induction;30,31 we do not believe 
that the use of such a scarce resource is appropriate for 
this purpose.32 The evidence of successful (if short-lived) 
hormone production by the ovarian autografts in those 
reports does, however, suggest that follicular development 
is possible, potentially allowing for oocyte maturation, 
ovulation, and fertility.
In conclusion, our data show that speciﬁ c selection 
criteria can be applied at diagnosis to girls and young 
women with cancer to identify the fairly small proportion 
of patients who are likely to survive but are at high risk of 
premature ovarian insuﬃ  ciency. Whether ovarian tissue 
cryopreservation can give an opportunity for fertility in 
the future for these patients still needs to be determined.
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